Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHBP | P24387 | 1/20 | 0.52 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | EDNRA | P25101 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | OGA | O60502 | 2/20 | 0.45 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7502509 | 0.82 | RAB9A (0.53) | CRHBPCRHR2RAB9ANPC1CYP3A4 | |
| SCHEMBL6138702 | 0.82 | RAB9A (0.56) | CRHBPCRHR2RAB9ANPC1CYP3A4 | |
| SCHEMBL12053329 | 0.81 | CYP3A4 (0.55) | RAB9ANPC1CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL8789026 | 0.81 | RAB9A (0.55) | CRHBPCRHR2RAB9ANPC1CYP3A4 | |
| SCHEMBL21632377 | 0.80 | MAPK9 (0.55) | CYP3A4CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL17466005 | 0.80 | MEN1 (0.58) | NPC1HTTKMT2AMAPTSMN1; SMN2 | |
| SCHEMBL7332440 | 0.80 | CYP3A4 (0.53) | CRHBPCRHR2RAB9ANPC1CYP3A4 | |
| SCHEMBL10034148 | 0.80 | MEN1 (0.42) | CYP3A4CYP1A2CYP2C19KMT2AMAPT | |
| SCHEMBL5285045 | 0.79 | MEN1 (0.41) | CRHBPCRHR2CYP3A4CYP1A2CYP2C19 | |
| SCHEMBL24580937 | 0.78 | CYP3A4 (0.52) | RAB9ANPC1CYP3A4CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220031679-A1 | PHARMACEUTICAL COMPOSITIONS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL) BENZOIC ACID AND ADMINISTRATION THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-02-03 | — | — | US | disclosed |
| US-20180111920-A1 | DEUTERATED VX-661 | CONCERT PHARMACEUTICALS, INC. | 2018-04-26 | — | — | US | disclosed |
| EP-1313560-B1 | CATALYST FOR AROMATIC C-O, C-N, and C-C BOND FORMATION | UNIV YALE (US) | 2007-12-19 | — | — | EP | disclosed |
| US-6962923-B2 | Pyrazole compositions | PFIZER INC. (US) | 2005-11-08 | — | — | US | disclosed |
| EP-1313560-A4 | CATALYST FOR AROMATIC C-O, C-N, and C-C BOND FORMATION | UNIV YALE (US) | 2005-02-09 | — | — | EP | disclosed |
| US-20030232848-A1 | Pyrazole compositions | PFIZER INC. | 2003-12-18 | — | — | US | disclosed |
| US-6610518-B2 | Using Cytochrome p450 | PFIZER INC. | 2003-08-26 | — | — | US | disclosed |
| US-6573270-B1 | Endothelin receptor antagonists | PFIZER INC. | 2003-06-03 | — | — | US | disclosed |
| EP-1313560-A1 | CATALYST FOR AROMATIC C-O, C-N, and C-C BOND FORMATION | YALE UNIVERSITY (US) | 2003-05-28 | — | — | EP | disclosed |
| US-6562989-B2 | Bicyclopentyl iron ligand and transition metal catalyst | YALE UNIVERSITY | 2003-05-13 | — | — | US | disclosed |
| US-20030008768-A1 | Catalyst for aromatic C-O, C-N, and C-C bond formation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-01-09 | — | — | US | disclosed |
| WO-2002011883-A1 | CATALYST FOR AROMATIC C-O, C-N, and C-C BOND FORMATION | YALE UNIVERSITY (US) | 2002-02-14 | — | — | WO | disclosed |
| EP-1160331-A1 | Enzymatic oxidations | Pfizer Limited (GB) | 2001-12-05 | — | — | EP | disclosed |
| EP-1072597-A1 | Pyrazoles and their use as endothelin antagonists | Pfizer Limited (GB) | 2001-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232848-A1 | Pyrazole compositions | EDNRB, EDNRA, AGTR1 | CRHBP 2538/4885CRHR2 279/4885RAB9A 2212/4885 |
| US-20180111920-A1 | DEUTERATED VX-661 | CFTR, DDX3X, VIL1 | CRHBP 4787/4885CRHR2 4168/4885RAB9A 1598/4885 |
| US-20220031679-A1 | PHARMACEUTICAL COMPOSITIONS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL) BENZOIC ACID AND ADMINISTRATION THEREOF | CFTR, GLI2, GPR39 | CRHBP 4797/4885CRHR2 4881/4885RAB9A 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.